Wire · opportunities
FDA Approves New First-Line Treatment Options for HER2-Positive AdvancedGastric and ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 September 2026 · Fusion42 review
The FDA approved new first-line treatment options involving zanidatamab-hrii for adults with HER2-positive advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma. These approvals include a four-drug combo with zanidatamab, tislelizumab, and chemotherapy, showing improved survival and progression-free survival over prior standards.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 27 Sep 2026 and 8 Oct 2026.
◆ ◆ The Wire takeaway
You now have new FDA-approved drug combos extending survival for advanced HER2-positive gastric cancers. Update your clinical pathways and patient testing protocols immediately to include zanidatamab-based options.
◆ Coverage
2 sources · first reported 27 Sep 2026 · latest 8 Oct 2026
◆ Related on Wire
◆ Topics